Aspargo Laboratories

Englewood, NJ

Aspargo Laboratories commercialize the rights of an oral suspension spray formulation of erectile dysfunction medication Sildenafil citrate. Spray formulation offers convenient drug administration, flexible-dose titration, and accessibility for patients with dysphagia (trouble swallowing). The company is developing patient-focused solutions and medicines by combining our innovative science and technology. Its initial product candidate is a proprietary oral suspension spray formulation of sildenafil citrate, the active ingredient in VIAGRA Currently, it has approved for sale in 9 European countries and 8 Latin American countries, with pending approvals in Portugal, Mexico, Italy, Czech Republic, Slovak Republic, Greece, Australia, and China. Applications for approval are planned for Croatia, France, Germany, and Austria.